Peritonitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 72: | Line 72: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[TMP-SMX-DS]] 1 tab po 5 days/week'''''<BR> OR <BR>▸'''''[[Ciprofloxacin]] 750 mg po once/week''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[TMP-SMX-DS]] 1 tab po 5 days/week'''''<BR> OR <BR>▸'''''[[Ciprofloxacin]] 750 mg po once/week''''' | ||
|} | |} | ||
|} | |} | ||
Line 131: | Line 109: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Severe Disease''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Severe Disease''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]I.M., I.V.: 1-2 g every 4-6 hours or 50-250 mg/kg/day in divided doses (maximum: 12 g/day) ''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ Metronidazole]]''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ Metronidazole]]I.V.: 500 mg every 8-12 hours or 1.5 g every 24 hours for for 4-7 days''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | ||
Line 150: | Line 128: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aminoglycoside]]''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aminoglycoside]]''''' | ||
|- | |||
|} | |||
|} | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table3" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Dialysis (CAPD) Associated ''}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Gram-positive cocci''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ Vancomycin]]I.V.: 2000-3000 mg daily (or 30-60 mg/kg/day) in divided doses every 8-12 hours''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Gram-negative bacilli''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] I.V.: 2 g every 12 hours for 7-10 days. ''''' <br>OR<br>▸''''' [[Ceftazidime]] .V.: 2 g every 8 hours for 4-7 days ''''' <br>OR<br> ▸'''''[[carbapenem]] '''''<br>OR<br>▸'''''[[Aztreonam]] 1 g I.V. or I.M. or 2 g I.V. every 8-12 hours'''''<br>OR<br>▸''''[[Ciprofloxacin]] I.V.: 400 mg every 12 hours for 7-14 days'''''<br>OR<br>▸'''''[[Gentamicin]] 3 mg/kg/day in 1-3 divided doses''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Add an antifungal only if yeast seen on Gram-stain ''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Continuous therapy until culture results available ''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Beta-lactam]] continuous therapy ''''' <br>OR<br>▸'''''[[Aminoglycoside]]''''' intermittent therapy]] ''''' | |||
|- | |- | ||
|} | |} |
Revision as of 05:24, 6 February 2014
Peritonitis Main Page |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Medical Therapy
Depending on the severity of the patient's state, the management of peritonitis may include:
- General supportive measures such as vigorous intravenous rehydration and correction of electrolyte disturbances.
- Antibiotics are usually administered intravenously, but they may also be infused directly into the peritoneum. The empiric choice of broad-spectrum antibiotics often consist of multiple drugs, and should be targeted against the most likely agents, depending on the cause of peritonitis; once one or more agents are actually isolated, therapy will of course be targeted on them.
Antibiotic therapy
Spontaneous Bacterial Peritionitis
- An empiric antibiotic therapy should be started immediately as soon as the diagnosis is made. Third generation cephalosporin ( ceftriaxone 1 g IV daily or cefotaxime 1 - 2 gm IV q6-8 hr ) are the preferred first line of treatment. [1]
- Repeat paracentessis if no improvement after 48- 72 hrs , specially if the culture was negative.[1]
- Ciprofloxacin can be used as a substitute for cephalosporin in the abscence of vomiting , shock or hepatic encephalopathy.[1]
- Start with empirical antibiotic therapy for patients with fever , abdominal pain and tenderness inspite of neutrophils < 250 cells/ mm3.[1]
- Albumin 1.5 g/kg body weight should be started at diagnosis and 1 gm/ kg body weight on day 3 to prevent renal failure.[2]
Peritonitis ▸ Primary Spontaneous Bacterial ▸ Secondary ▸ Dialysis (CAPD) Associated
|
|
References
- ↑ 1.0 1.1 1.2 1.3 Runyon, BA.; Shuhart, MC.; Davis, GL.; Bambha, K.; Cardenas, A.; Davern, TJ.; Day, CP.; Han, SH.; Howell, CD. (2009). "Management of adult patients with ascites due to cirrhosis: an update". Hepatology. 49 (6): 2087–107. doi:10.1002/hep.22853. PMID 19475696. Unknown parameter
|month=
ignored (help) - ↑ Grange, JD.; Amiot, X. (2000). "[Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis]". Gastroenterol Clin Biol. 24 (3): 378–9. PMID 10866518. Unknown parameter
|month=
ignored (help)